OncLive® Welcomes Sarah Cannon Cancer Network to Strategic Alliance Partnership Program

Article

In Partnership With:

OncLive® will team with Sarah Cannon, the global cancer enterprise of Hospital Corporation of America, as it further expands its Strategic Alliance Partnership Program for raising awareness of cancer treatment and research.

PLAINSBORO, N.J. — (July 1, 2015) – OncLive® will team with Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), as it further expands its Strategic Alliance Partnership Program for raising awareness of cancer treatment and research, OncLive announced today.

With this new partnership, OncLive’s editorial and marketing teams will collaborate with Sarah Cannon to share the latest news about Sarah Cannon’s innovative clinical practices and wide-ranging clinical trial programs for cancer.

Sarah Cannon is a global network of cancer experts offering cancer patients in communities across the U.S. and U.K. integrated cancer services with convenient access to cutting-edge therapies. Sarah Cannon has been conducting community-based clinical trials for more than 20 years and offers a multidisciplinary approach to cancer care through its network, which serves more than 100,000 newly diagnosed cancer patients every year.

“Working with Sarah Cannon provides us with an opportunity to present the latest developments surrounding many of the important clinical trials taking place in the United States and internationally,” said Mike J. Hennessy Jr., president of Intellisphere Oncology and Healthcare Specialty Group, which includes OncLive, and Specialty Pharmacy at Michael J. Hennessy Associates, Inc. “We’ll also be able to share news of the many advances in drug-based treatments, thanks to Sarah Cannon’s status as an industry leader in drug development research.”

“People who live with cancer — those who work to prevent it, fight it, and survive it – are at the heart of every decision we make, and by pairing clinical excellence with cutting-edge research, we are redefining cancer care around the world,” said Dee Anna Smith, CEO of Sarah Cannon. “Partnering with OncLive allows us to share our clinical trial and clinical care expertise with a broader audience, with the goal of raising the standard of care for cancer patients.”

Sarah Cannon joins over 50 other leading cancer centers, nursing schools and physician groups around the country in partnering with OncLive.

Hennessy added, “The Strategic Alliance Partnership program serves everyone committed to fighting cancer. When we work together and share our knowledge broadly, we are better armed to improve our efforts to overcome this devastating disease.”

About OncLive

OncLive.com is the official website for Intellisphere’s Oncology Specialty Group, which publishes Oncology & Biotech News, OncologyLive, Oncology Nursing News and Contemporary Oncology. OncLive offers oncology professionals resources and information they need to provide the best care for their patients. Intellisphere, LLC, a leading provider of healthcare publishing, research and education, is part of the Michael J. Hennessy Associates, Inc. family of businesses, based in Plainsboro, N.J. MJH also includes the acclaimed CURE Media Group, which combines science and humanity to make cancer understandable. Its flagship product is CURE™ magazine, the largest consumer publication in the U.S. focused entirely on cancer, reaching cancer patients, cancer centers and advocacy groups. To learn more, please visit www.OncLive.com.

About Sarah Cannon

Sarah Cannon, the global cancer enterprise of Hospital Corporation of America (HCA), offers integrated cancer services with convenient access to cutting-edge therapies for those facing cancer in communities across the United States and United Kingdom. Sarah Cannon’s cancer programs address every aspect of cancer care from diagnosis through survivorship, including individualized patient navigation provided by oncology-trained nurses, more than 900 stem cell transplants performed annually throughout the Sarah Cannon Blood Cancer Network, as well as access to more than 500 clinical trials, and molecular profiling capabilities. Through its services, Sarah Cannon is providing state-of-the-art cancer care close to home for hundreds of thousands of patients, a number unmatched by any single cancer center. To learn more about Sarah Cannon, visit sarahcannon.com.

Media Contacts

For Sarah Cannon: Hayley Lyons, 615-390-6522, Hayley.Lyons@sarahcannon.com

For CURE: Becky Taylor, 609-240-6886, becky@btaylorpa.com

Related Videos
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Martin H. Voss, MD, an expert on renal cell carcinoma
Laurence Albigès, MD, PhD, an expert on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma